The Trump administration is considering sweeping restrictions on medicines originating from China, a move that could dramatically reshape the U.S. pharmaceutical industry and patient access to treatments.
A draft executive order, obtained by The New York Times, would block American drugmakers from acquiring Chinese-invented experimental treatments and subject such deals to heightened national security review. The proposal also calls for incentives to boost U.S. manufacturing of critical drugs, including antibiotics and acetaminophen.
The plan has sparked an intense lobbying battle. Billionaire investors close to President Donald Trump, including Peter Thiel, Sergey Brin, and the Koch family, have urged a hard line, warning that China’s surging biotech sector threatens U.S. innovation, according to the report. Many hold investments in struggling American biotech firms.
Read more at Newsmax© 2025 Newsmax. All rights reserved.
